Anupam Rasayan India Dividend 2026 – ₹1.50 Final Dividend | Yield, Record Date & Sustainability

Anupam Rasayan India Limited (NSE: ANURAS | BSE: 543275 | ISIN: INE930P01018) is a Surat-based specialty chemicals company engaged in custom synthesis and manufacturing (CSM). Its life-science vertical — agrochemicals, personal care and pharmaceutical intermediates — contributes roughly 91% of revenue, with the balance from other specialty chemicals. The company operates multiple plants in Gujarat and has expanded aggressively through acquisitions, including Tanfac Industries and the US-based Jayhawk Fine Chemicals. The board that recommended this dividend also approved acquiring up to 74.20% of Bliss GVS Pharma, signalling a capital-heavy growth phase. For income-focused readers, Anupam Rasayan India Limited is best understood as a growth chemical maker that pays a small, symbolic dividend rather than a yield stock.

The ₹1.50 final dividend is comfortably covered by earnings — coverage is roughly 10x — but that comfort is misleading. Anupam Rasayan India Limited generated negative free cash flow of about ₹221 crore in FY26 because capital expenditure (₹555 crore) exceeded operating cash flow (₹334 crore). In plain terms, the profits are real on paper, but the company is spending more cash on growth and working capital than it earns. The dividend of ₹17 crore is therefore effectively funded from the balance sheet and fresh borrowings, not surplus cash. This is a growth-stage payout — a token shareholder gesture, not a distribution of excess capital. Readers seeking dividend income should weigh the sub-0.15% yield against that context.

The near-term dividend outlook for Anupam Rasayan India Limited remains modest. With the Bliss GVS Pharma acquisition (up to 74.20% stake), fresh ₹160 crore NCD issuance, and the Jayhawk and Tanfac integrations all consuming capital, management is prioritising expansion over distribution. The dividend payout ratio has stayed in a narrow 7–10% band for years, and that discipline is unlikely to change while the balance sheet carries rising debt. If the large capex cycle matures and free cash flow turns durably positive, there is scope for higher payouts. Until then, investors should expect the dividend to stay symbolic and treat any capital appreciation — not yield — as the primary return driver for Anupam Rasayan India Limited.

At its board meeting held on 23 May 2026, the board of Anupam Rasayan India Limited recommended a final dividend of ₹1.50 per equity share (15% of the ₹10 face value) out of the profits for the financial year 2025-26. The payout is subject to shareholder approval at the forthcoming 23rd Annual General Meeting. The same board meeting also approved audited FY26 results (with an unmodified audit opinion from Natvarlal Vepari & Co.), the acquisition of up to 74.20% of Bliss GVS Pharma, the issue of ₹160 crore secured NCDs, and noted the resignation of the Deputy CFO. On a base of about 11.38 crore paid-up shares, the ₹1.50 dividend translates into a total outflow of roughly ₹17.08 crore for Anupam Rasayan India Limited.

As this is a final dividend, the record date, ex-date and payment date will be set around the 23rd AGM and were not part of the 23 May 2026 board outcome. Investors should track the exchange filings of Anupam Rasayan India Limited for these dates.

At the current market price of about ₹1,182 (NSE, 16 Sep 2026), the ₹1.50 dividend gives a yield of just 0.13%. Measured against the price near the announcement (~₹1,229), the yield was about 0.12%. Either way, the yield is negligible. Crucially, this low figure is not the result of a rising share price masking a strong payout — the dividend itself is small and has stayed under ₹2.10 in every year since listing. For Anupam Rasayan India Limited, a ₹1 lakh investment (about 85 shares) would earn roughly ₹127 a year in dividend before tax. The takeaway: yield is not the reason to own this stock, and readers should not confuse the headline dividend with meaningful passive income.

Anupam Rasayan India Limited has paid a dividend every year since its 2021 listing, which makes it a consistent payer — but not a growing one. The annual payout has been erratic: ₹0.50 (FY21), ₹1.40 (FY22), a peak of ₹2.10 (FY23), then a decline to ₹1.25 (FY24) and a low of ₹0.75 (FY25), before recovering to ₹1.50 in FY26. This is a zig-zag, not a staircase. The FY25 cut coincided with weaker earnings, showing the dividend flexes with profit rather than following a fixed policy. There have been no special dividends and no suspensions. For income planning, the pattern of Anupam Rasayan India Limited is best described as consistent but cyclical and low — reliable in occurrence, unreliable in amount.

FY26 was a strong headline year but a study in operating leverage working in reverse. Consolidated revenue grew 64.6% to ₹2,365 crore, yet EBITDA rose only ~31% to about ₹525 crore, compressing the EBITDA margin from 27.9% to 22.2%. In simple terms, Anupam Rasayan India Limited sold far more but kept less of each rupee, largely because the newly consolidated, lower-margin acquisitions (Tanfac, Jayhawk) diluted the group mix and other expenses rose sharply. Profit attributable to owners did jump to ₹170 crore, but a swelling ₹1,296 crore minority interest means group profit is increasingly shared with outside stakeholders. Interest coverage is modest at about 2.6x. Growth is real; quality of that growth is the open question.

The balance sheet of Anupam Rasayan India Limited is expansion-heavy and leveraged. Consolidated total borrowings stood at about ₹1,815 crore at FY26-end, against cash and investments of roughly ₹412 crore, leaving net debt near ₹1,437 crore. Borrowings have climbed steeply over three years to fund capex and acquisitions, and the company issued a further ₹160 crore of NCDs alongside this dividend. Cash coverage of the dividend is high at about 24x, so the payout is trivially affordable in isolation — but that misses the point: the same balance sheet is simultaneously taking on debt. A company distributing ₹17 crore while net debt exceeds ₹1,400 crore is making a symbolic gesture, and readers should judge Anupam Rasayan India Limited on debt trajectory, not dividend cover.

The ₹1.50 dividend of Anupam Rasayan India Limited is sustainable in the narrow sense — it costs just ₹17 crore, earnings cover it about 10x, and cash reserves cover it about 24x. But sustainability of a token payout is a low bar. The stress signals are that free cash flow is negative, net debt exceeds ₹1,400 crore, and earnings are cyclical (the FY25 dividend was cut to ₹0.75). The payout survives because it is small enough to be paid from the balance sheet regardless of cash generation. We classify it Moderately Sustainable: the dividend is unlikely to stop, but it is equally unlikely to grow meaningfully while capex and debt dominate capital allocation.

Promoters held 59.07% of Anupam Rasayan India Limited as of June 2026. Of the ₹17.08 crore total dividend, promoters will therefore receive about ₹10.09 crore, while all non-promoter shareholders (public + institutions) share the remaining ₹6.99 crore. Because the payout is small, the promoter benefit is modest in absolute terms and the distribution is broadly proportionate to holding — there is no disproportionate promoter enrichment here. However, it is worth noting that promoter holding has drifted down from over 61% in FY25 to 59.07%, and a promoter share pledge was reported during the year for NCD security cover. For minority shareholders of Anupam Rasayan India Limited, the dividend is a fair but immaterial slice of value; capital allocation into growth matters far more.

• Rising leverage: Net debt near ₹1,437 crore with fresh ₹160 crore NCDs; interest coverage only ~2.6x.
• Negative free cash flow: FY26 FCF of about −₹221 crore means growth and dividends lean on borrowings and reserves.
• Margin compression: EBITDA margin fell from 27.9% to 22.2% as lower-margin acquisitions diluted the mix.
• Integration & acquisition risk: Bliss GVS Pharma, Jayhawk and Tanfac must be integrated; goodwill of ₹540 crore sits on the books.
• Customer & sector concentration: CSM revenue depends on a limited set of large global agrochemical clients; demand is cyclical.
• Working-capital intensity: High inventory and receivable days repeatedly strain operating cash flow.

• Free cash flow trend: Whether FCF turns positive as the capex cycle matures.
• Debt reduction: Movement in net debt and interest coverage over the next 2–4 quarters.
• EBITDA margin recovery: Return toward the historical 26–28% band as acquisitions integrate.
• Bliss GVS & Jayhawk integration: Revenue and margin contribution, and any further equity dilution or NCI growth.
• Working-capital cycle: Inventory and receivable days normalising toward earlier levels.
• Payout policy: Any shift in dividend payout ratio beyond the 7–10% band that has held for years.

The ₹1.50 final dividend from Anupam Rasayan India Limited is best read as a shareholder courtesy, not an income stream. It yields about 0.13%, costs the company just ₹17 crore, and is comfortably covered by earnings and cash. Yet the same year saw negative free cash flow of ₹221 crore, net debt above ₹1,400 crore, and margins compressing as acquisitions scaled the business. The positives are consistent dividend history, strong revenue growth and a recovering operating cash flow; the negatives are leverage, cash burn and below-peer returns. Income investors will find little here. Growth investors must decide whether the acquisition-led expansion of Anupam Rasayan India Limited will convert into durable free cash flow. We present the facts and leave the decision to you.

This article is for informational and educational purposes only and does not constitute investment, financial, legal or tax advice, nor a recommendation to buy, sell or hold any security. Figures are drawn from the company's audited FY26 results dated 23 May 2026 and publicly available sources, and may contain errors or become outdated. Market prices, yields and ratios change continuously. ShareBazaar Online does not guarantee the accuracy or completeness of any information here and accepts no liability for any loss arising from its use. Dividend approval, record date and payment are subject to shareholder and regulatory processes. Please verify all data with primary sources and consult a SEBI-registered investment adviser before making any investment decision.